H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses for the target increase. The analyst says IO’s Phase 3 advanced melanoma data is on track for Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT: